RedHill starts Phase II trial of Yeliva for cholangiocarcinoma

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) began an open-label, U.S. Phase IIa trial of Yeliva (ABC294640) to treat cholangiocarcinoma. The

Read the full 207 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE